Geninus
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Geninus is a biotech company that reads and interprets human genetic data to help drug developers find new medicine targets and to help clinicians detect cancer, using tools such as next-generation sequencing (a method of rapidly decoding DNA) and AI-powered digital pathology analysis.
Its customers include pharmaceutical companies, academic researchers, and clinical laboratories. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company organises its business around three lines: software platforms for pharma drug discovery, genomic analysis solutions for researchers, and cancer diagnostic services such as its CancerSCAN and LiquidSCAN tests.
Summary is AI-generated and may contain errors · figures from DART filings
Geninus was spun off from the Samsung Genome Institute at Samsung Seoul Hospital, which is the origin of its proprietary bioinformatics database and analytical capabilities.
Geninus in five facts
What does Geninus do?
Geninus is a biotech company that reads and interprets human genetic data to help drug developers find new medicine targets and to help clinicians detect cancer, using tools such as next-generation sequencing (a method of rapidly decoding DNA) and AI-powered digital pathology analysis.
Where is Geninus listed and in which sector?
Geninus (Korean name: 지니너스) trades under KRX code 389030 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Geninus?
Its market capitalisation was US$46.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Geninus's latest annual revenue and operating profit?
For fiscal year 2025, Geninus reported revenue of US$7.9M, an operating loss of US$8.8M and a net loss of US$13.1M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 20952.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material event reportCapital raise · May 12
- Material event report (CB call option holder designated)Capital raise · May 8
- [Attachment added] Material event report (rights offering)
Geninus disclosed convertible bonds to raise US$13.5M, about 24.1% of its market value.
Capital raise · Mar 9 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 30